BACKGROUND: Hypothyroidism is a risk factor for atherosclerotic cardiovascular disease. This study investigated the effects of L-thyroxine replacement therapy on lipid profile and endothelial function after thyroidectomy in patients with overt transient non-autoimmune hypothyroidism. METHODS: Twenty-two patients with non-toxic multinodular goitre treated by total or near-total thyroidectomy and 22 healthy individuals matched for age, sex and body mass index were studied. Lipid profile and endothelial function were determined in each patient at the euthyroid phase before thyroidectomy (stage 1), the hypothyroid phase 3 weeks after surgery (stage 2), and the euthyroid phase 3 months (stage 3) and 6 months (stage 4) after the start of thyroxine treatment. RESULTS: The lipid profile and endothelial function deteriorated between stage 1 and stages 2 and 3. Findings at stage 4 were similar to those at stage 1. There was a positive correlation between serum thyroid-stimulating hormone (TSH) and total cholesterol (r(s) = 0.588, P < 0.001), and a negative correlation between serum TSH and flow-mediated arterial dilatation (r(s) = 0.506, P < 0.001). Total cholesterol and TSH were independent determinants of endothelial function. CONCLUSION: A 3-week hypothyroid period after thyroidectomy led to a more atherogenic lipid profile and impaired endothelial function that persisted for at least 3 months. Copyright (c) 2007 British Journal of Surgery Society Ltd.
BACKGROUND:Hypothyroidism is a risk factor for atherosclerotic cardiovascular disease. This study investigated the effects of L-thyroxine replacement therapy on lipid profile and endothelial function after thyroidectomy in patients with overt transient non-autoimmune hypothyroidism. METHODS: Twenty-two patients with non-toxic multinodular goitre treated by total or near-total thyroidectomy and 22 healthy individuals matched for age, sex and body mass index were studied. Lipid profile and endothelial function were determined in each patient at the euthyroid phase before thyroidectomy (stage 1), the hypothyroid phase 3 weeks after surgery (stage 2), and the euthyroid phase 3 months (stage 3) and 6 months (stage 4) after the start of thyroxine treatment. RESULTS: The lipid profile and endothelial function deteriorated between stage 1 and stages 2 and 3. Findings at stage 4 were similar to those at stage 1. There was a positive correlation between serum thyroid-stimulating hormone (TSH) and total cholesterol (r(s) = 0.588, P < 0.001), and a negative correlation between serum TSH and flow-mediated arterial dilatation (r(s) = 0.506, P < 0.001). Total cholesterol and TSH were independent determinants of endothelial function. CONCLUSION: A 3-week hypothyroid period after thyroidectomy led to a more atherogenic lipid profile and impaired endothelial function that persisted for at least 3 months. Copyright (c) 2007 British Journal of Surgery Society Ltd.
Authors: Seth S Martin; Natalie Daya; Pamela L Lutsey; Kunihiro Matsushita; Anna Fretz; John W McEvoy; Roger S Blumenthal; Josef Coresh; Philip Greenland; Anna Kottgen; Elizabeth Selvin Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958
Authors: Hyuk-Jae Chang; Kyung Won Kim; Sung Hee Choi; Soo Lim; Kyoung Un Park; Do Joon Park; Dong Joo Choi; Hak C Jang; Bo Youn Cho; Young Joo Park Journal: Yonsei Med J Date: 2010-07 Impact factor: 2.759
Authors: Ranjith Sukumar; Amit Agarwal; Sushil Gupta; Anjali Mishra; Gaurav Agarwal; A K Verma; S K Mishra Journal: World J Surg Date: 2010-03 Impact factor: 3.352
Authors: Elizabeth A McAninch; Kumar B Rajan; Corinne H Miller; Antonio C Bianco Journal: J Clin Endocrinol Metab Date: 2018-08-15 Impact factor: 5.958